RSS Feeds
Search

Companies

Guidant

Summary

Guidant was founded in 1994. Guidant's mission is to provide therapeutic medical solutions to customers, patients and health care systems around the world. The company has pursued a strategy for growth that includes internal product development, collaborations and acquisitions within the medical technology industry.

R&D

Guidant develops, manufactures and markets a range of products and services that enable less invasive care for coranary diseases. The company's product range includes coranary stent systaems, ANCURE for the treatment of abdominal aortic aneurysm (AAA) repair, automatic implantable cardiovascular defibrillators (ACIDs), directional coranary atherectomy (DCA) devices, cardiac resynchronization therapy defibrillators (CRT-Ds) as well as numerous other products.

Partnerships

Guidant has a licensing agreement with Everolimus for drug eluting stents as well as alliances with HeartCenterOnline, Merck KGaA, University of Medicine and Dentistry of New Jersey.a licensing agreement with Everolimus for drug eluting stents as well as alliances with HeartCenterOnline, Merck KGaA, University of Medicine and Dentistry of New Jersey.

Senior management

James M. Cornelius (Chairman and Chief Executive Officer)
Mr. Cornelius is Chairman of the Board and CEO (Interim) of Guidant Corporation. On November 15, 2005, Guidant agreed to be acquired by Johnson & Johnson (J&J) in a re-priced transaction for $21 billion of cash and J&J stock. At that time Mr. Cornelius, Board Chairman, agreed to serve as Guidant's full-time senior executive until deal closing. Mr. Cornelius had been the company's senior executive from 1995 to 2000. Mr. Cornelius was a member of the Board of Directors of Lilly, its Executive Committee, and Chief Financial Officer from 1983 until joining Guidant. In 1978 he was named the initial director of acquisitions for Lilly's Medical Device and Diagnostics Division (MDD), the predecessor group to Guidant. He served as president and CEO of IVAC Corporation in San Diego from 1980-82, previously part of Lilly's MDD business. He has been active as a Board member of several Indianapolis civic organizations and has served United Way of Central Indiana in multiple leadership positions. He also served as Treasurer of the Board of Governors for the Indianapolis Museum of Art for more than nine years. He is President of the Cornelius Family Charitable Foundation. Mr. Cornelius has received several honorary Doctorate degrees to recognize his civic and philanthropic activities. They include Michigan State University (2001), the University of Indianapolis (1998), and Marian College (1996). He was also honored by receipt of the Anti-Defamation League's 2003 Man of Achievement Award, and the 2005 Hoosier Heritage Lifetime Achievement Award.

Mark C. Bartell (President, U.S. Sales Operations)
Mr. Bartell was appointed to his current position in March, 2000. Prior to this assignment, he served as Vice President, Marketing for Guidant's Cardiac Rhythm Management group. Mr. Bartell joined Cardiac Pacemakers, which is now part of Guidant's Cardiac Rhythm Management group, in 1985 as a Financial Analyst. He held positions in new product planning, product management and as a Sales Representative. Most recently, Mr. Bartell served as Vice President and General Manager of the guide wire business unit at Guidant's Vascular Intervention group. Mr. Bartell earned his Bachelor of Science degree from the University of Florida, and a Master of Business Administration from the University of Michigan.

Keith E. Brauer, M.B.A. (Vice President and Chief Financial Officer)
Mr. Brauer was named Vice President and Chief Financial Officer for Guidant in July 1994. In addition to this role, Mr. Brauer is also responsible for information systems and Guidant's business development organization, Compass. Prior to that, he was the Executive Director of Finance and Chief Accounting Officer for Eli Lilly and Company. Mr. Brauer joined Lilly as an Associate Financial Analyst for International Operations in 1974. He was named a Staff Financial Analyst in 1976 in the pharmaceutical division, and became a Marketing Analyst the following year. In 1978, he was named Coordinator of Business Planning for Lilly's Medical Devices and Diagnostics Division (MDD). He later served as Administrator of MDD. In 1981, he became Controller of Elizabeth Arden, a former Lilly subsidiary. In May 1984, Mr. Bauer was named Vice President of Finance and Treasurer for Physio-Control, a Lilly subsidiary in Redmond, Washington. Returning to the corporate headquarters in Indianapolis in May 1986, he became Director of Corporate Affairs for Lilly, and was named Executive Director of International Finance in June 1988. A native of Palatine, Illinois, Mr. Brauer received a Bachelor of Science degree from Indiana University in 1970, and a Master of Business Administration degree from the University of Michigan in 1973. Mr. Brauer currently serves on the University of Michigan Business School Corporate Advisory Board, the Indiana Museum of Art Board of Trustees, the Board of Directors and Finance Committee of Community Hospitals Indianapolis, and the Board of Directors of Indiana University's Advanced Research and Technology Institute. He is a member of the Financial Executives Institute and Beta Gamma Sigma.

John M. Capek, Ph.D., M.B.A. (President of Vascular Intervention)
Mr. Capek, Ph.D., was named president, Guidant Vascular Intervention, in May 2005. Mr. Capek previously served as vice president and general manager of Bioabsorbable Vascular Solutions (BVS), a recently formed subsidiary of Guidant. Mr. Capek also was a key member of the team negotiating the company's pending merger with Johnson & Johnson. Prior to that, he served as president, Vascular Intervention, from 2000 to 2003. He was vice president and general manager, Guidant Germany since 1997. Mr. Capek also served seven years as vice president, Marketing, Guidant Cardiac Rhythm Management Group. Before joining Guidant, Mr. Capek served as manager, New Product Technology, at Eli Lilly & Company, Indianapolis. Mr. Capek received his Bachelor of Science in Biomedical Engineering in 1983, a Masters of Engineering in Biomedical Engineering in 1984, a Masters of Engineering in Electrical Engineering in 1985, a Ph.D. in Biomedical Engineering in 1987 and an MBA in 1987, all from Rensselaer Polytechnic Institute in Troy, N.Y.

Maria Degois-Sainz, M.BA. (President, Cardiac Surgery)
Ms. Degois-Sainz began her career as a Marketing Analyst for Eli Lilly and Company in 1989. Shortly thereafter, she assumed an assignment within the company's medical device division in France, which eventually became part of Guidant Corporation. She has since held various international sales, marketing and management assignments within the company, including European Marketing Director, Vascular Intervention, Guidant, and Vice President, Guidant Intermedics Europe. Ms. Degois-Sainz was named Vice President, Global Marketing, Vascular Intervention, Guidant, in late 2000. Ms. Degois-Sainz holds a Master in Languages from the University of Madrid and an MBA from Thunderbird American Graduate School.

Bernard E. Kury (Vice President and General Counsel)
Mr. Kury joined Guidant as Vice President and General Counsel in April 2004. Previously, he was a partner in Dewey Ballantine, LLP, a New York-based law firm, where he focused on corporate finance, mergers and acquisitions, venture capital and securities matters. Mr. Kury has a long-standing relationship with Guidant and its predecessor companies that spans more than 20 years. He served as lead outside counsel on Guidant's initial public offering in December 1994, and its spin off from Eli Lilly and Company in 1995. In addition, he was lead outside counsel on numerous Guidant acquisitions. Mr. Kury is a member of the American Bar Association, the Association of the Bar of the City of New York, and the New York State Bar Association. Mr. Kury holds an A.B. degree from Princeton University and an LL.B. degree from the University of Pennsylvania Law School, where he served as Case Editor of the school's Law Review.

Ronald K. Lattanze, M.B.A. (Director)
Mr. Lattanze was appointed President of Guidant Endovascular Solutions effective January 1, 2005. Prior to assuming his current role, Mr. Lattanze served as President of Guidant Japan. He also served as Vice President and Chief Operating Officer of Guidant's Japan operations. Before living and working in Japan, Mr. Lattanze served as Director, Asia operations in Hong Kong. Previous to his international experience, Mr. Lattanze served as Director, Stent Operations, for Guidant's Vascular Intervention business, where he was instrumental in the initial launches of Guidant's successful MULTI-LINKĀ® and MULTI-LINK DUET(TM) coronary stent systems. Mr. Lattanze was appointed to the Guidant Management Committee in February 2003. Before joining Guidant, Mr. Lattanze held financial and operation management positions at IVAC Corporation and was a Naval Officer for six years. Mr. Lattanze earned a Bachelor of Arts degree in history and an MBA from the University of North Carolina at Chapel Hill.

Beverly H. Lorell, M.D. (Vice President, Chief Medical and Technology Officer)
Dr. Lorell was appointed vice president, chief medical and technology officer in November 2003. In this role, Dr. Lorell is responsible for evaluating new and emerging technologies, determining product development priorities, and influencing the company's clinical research strategy across all of its businesses. She also serves as a strong advocate on public policy initiatives, which are critical to the company's long-term success. Additionally, Dr. Lorell is a member of Guidant's Compass board, the company's venture investing and business development group that looks at emerging therapies and their potential to improve patient care. In addition to her role at Guidant, Dr. Lorell is Professor of Medicine at Harvard University Medical School. Previously, Dr. Lorell served as director, Program in Heart Failure at Beth Israel Deaconess Medical Center. She also served as a member of Beth Israel's interventional cardiology team. Dr. Lorell is internationally recognized for her expertise in clinical care of heart failure as well as cardiac catheterization - interventional cardiology. She is also an expert in diagnosis and care of patients with coronary artery disease and acute ischemic syndromes. During her 20 years as a senior faculty member at Beth Israel Hospital and Beth Israel Deaconess Medical Center, she has conducted extensive research in the treatment of patients with advanced heart failure. She has also led a basic science research team which focused on discovery of mechanisms of cardiac protection in heart failure and ischemic heart disease. Her work has been published extensively and she has served as an invited lecturer at various heart conferences and symposiums around the world. Additionally, Dr. Lorell has served in leadership positions on numerous national advisory boards and committees, including the American Heart Association, Heart Failure Society of America and American College of Cardiology, which guide national standards for care of heart failure patients. She has served as advisor to the federal government in major leadership roles, including service on study section of the National Institutes of Health as well as the Cardiovascular and Renal Drugs Advisory Committee of the FDA. Dr. Lorell received a bachelor of arts with distinction from Stanford University in 1971, and earned her medical doctorate from Stanford University School of Medicine in 1975. She served as a medical intern and resident physician at Stanford University Hospital, and completed clinical and research fellowships in cardiology at Massachusetts General Hospital and Harvard Medical School.

Kathleen Lundberg (Chief Compliance Officer)
Ms. Lundberg was appointed Chief Compliance Officer, Guidant Corporation, in December 2000. Previously, she served as Senior Vice President, Human Resources, Guidant Corporation. Ms. Lundberg began her career with Guidant in 1981 as a Biostatistician for Cardiac Pacemakers, Inc., which is now part of Guidant's Cardiac Rhythm Management Group. Her subsequent positions included Coordinator for Scientific and Engineering Systems, Supervisor of ISS, Personnel Representative, Manager of Compensation, Manager of Human Resources, Manager of Leads Production, Director of Clinicals and Regulatory Affairs. Ms. Lundberg received a Bachelor of Science degree in Mathematics and a Master's degree in Biostatistics and Computer Science, both from the University of Minnesota.

William F. McConnell (Vice President and Chief Information Officer)
Mr. McConnell was named vice president and chief information officer for Guidant in September 1998. Prior to that Mr. McConnell was Managing Partner -- Business Consulting in the Indianapolis office of Arthur Andersen LLP.Mr. McConnell joined Arthur Andersen in 1971 as a staff member involved in consulting with clients in the planning, design and implementation of information systems. He was promoted to manager in 1975 and then was admitted as a Partner in Arthur Andersen in 1981. He became the Managing Partner -- Andersen Consulting in Indianapolis in 1983 and ran the Indiana practice for the firm for the next six years. In 1989, he left Andersen to join Resort Condominiums International (RCI) as Chief Financial Officer. He spent a year as CFO, was promoted to Chief Operating Officer in 1990 and spent the next six years running North American operations for RCI. He became Information Officer/Worldwide for RCI in 1996. Mr. McConnell left RCI in 1997 when it was acquired by HFS and rejoined Arthur Andersen in 1997.

R. Frederick McCoy (President, Cardiac Rhythm Management)
Mr. McCoy became President, Cardiac Rhythm Management in May 2000. Prior to this assignment, he served as President, Asia Pacific Operations in Tokyo, Japan. From 1995 to 1997, Mr. McCoy served as Vice President, U.S. Operations West. In 1993, he became General Manager, Northwest Operations, located in Seattle, Wash., for Eli Lilly and Company's Medical Devices and Diagnostic division. In 1991 he became Chief Financial Officer of Cardiac Pacemakers, now Guidant Cardiac Rhythm Management. Previously, he had held a series of positions with Lilly in Indiana, Alabama and California. A native of Laurinburg, Mr. McCoy was awarded a Bachelor of Science degree from the University of North Carolina in 1979. He is also a graduate of the Kellogg School of Management at Northwestern University. There he received a Master of Management degree in 1981. In addition to his duties at Guidant, he is a member of the Board of Trustees of the Minnesota Medical Foundation and a member of the Board of Trustees of St. Andrews Presbyterian College. He is member and immediate past chairman of the Kellogg Alumni Advisory Board, Northwestern University. Mr. McCoy is a member of the Board of Directors of Hutchinson Technology.

Ronald N. Spaulding (President, Europe, Middle East, Africa and Canada)
Mr. Spaulding was appointed to his current position in February 2003. Mr. Spaulding joined Guidant in 1994 as a Senior Research and Development Engineer. One year later, he was promoted to Director, Atherectomy and Accessories. In 1997, he was named Director, Stent Research and Development. In 1999, he was promoted to Vice President of Guidant's Compass group, the company's business and development and merger and acquisition arm. Mr. Spaulding was named President of Guidant's Cardiac Surgery business in 2000 and was appointed to the Guidant Management Committee in January 2002.

P. Douglas Wilson (Vice President of Human Resources)
Mr. Wilson was appointed vice president, Human Resources, Guidant Corporation in 2005. Prior to this assignment he served as vice president, Global Human Resources Services. Before joining Guidant, Mr. Wilson was President and Chief Operating Officer of Ronald Blue & Co., a nationally recognized fee-only wealth management firm based in Atlanta, Ga. Previously, he was with Eli Lilly and Company for 20 years. He began his career in sales and marketing and held a series of executive positions in human resources for Eli Lilly, including significant experience in the medical device unit, Lilly Research Laboratories and the Pharmaceutical Products Group. A native of Carmel, Ind., Mr. Wilson received both a Bachelor of Science degree and a Master's from Ball State University.

Ronald W. Dollens (President and Chief Executive Officer)
Mr. Dollens is president and chief executive officer of Guidant, a $2.7 billion company traded on the New York and Pacific Stock Exchanges. Prior to the formation of Guidant, Mr. Dollens served as president of Eli Lilly and Company's Medical Devices and Diagnostics Division (MDD). In 1985, Mr. Dollens was named senior vice president, sales, marketing and product development for Advanced Cardiovascular Systems. (ACS), a MDD company headquartered in Santa Clara, Calif. In 1988, he became president and chief executive officer of ACS. He assumed his current post as president and chief executive officer of Guidant when the company was formed in 1994. Mr. Dollens received a bachelor of science degree in pharmacy from Purdue University and a master of business administration degree in marketing from Indiana University. Mr. Dollens is a member of the Boards of Advanced Medical Technology Association (AdvaMed, formerly HIMA), Alliance for Aging Research, Healthcare Leadership Council, Indiana Health Industry Forum, Kennetic Concepts, Beckman Coulter, and United Way of Central Indiana. Active in civic affairs, he also serves on the Boards of Butler University, Eiteljorg Museum, St. Vincent Hospital Foundation and the Indiana State Symphony Society. Additionally, Mr. Dollens has been appointed by U.S. Health and Human Services Secretary Tommy G. Thompson to serve on the newly created Advisory Committee on Regulatory Reform.

Board of directors

James M. Cornelius (Chairman and Chief Executive Officer)
Mr. Cornelius is Chairman of the Board and CEO (Interim) of Guidant Corporation. On November 15, 2005, Guidant agreed to be acquired by Johnson & Johnson (J&J) in a re-priced transaction for $21 billion of cash and J&J stock. At that time Mr. Cornelius, Board Chairman, agreed to serve as Guidant's full-time senior executive until deal closing. Mr. Cornelius had been the company's senior executive from 1995 to 2000. Mr. Cornelius was a member of the Board of Directors of Lilly, its Executive Committee, and Chief Financial Officer from 1983 until joining Guidant. In 1978 he was named the initial director of acquisitions for Lilly's Medical Device and Diagnostics Division (MDD), the predecessor group to Guidant. He served as president and CEO of IVAC Corporation in San Diego from 1980-82, previously part of Lilly's MDD business. He has been active as a Board member of several Indianapolis civic organizations and has served United Way of Central Indiana in multiple leadership positions. He also served as Treasurer of the Board of Governors for the Indianapolis Museum of Art for more than nine years. He is President of the Cornelius Family Charitable Foundation. Mr. Cornelius has received several honorary Doctorate degrees to recognize his civic and philanthropic activities. They include Michigan State University (2001), the University of Indianapolis (1998), and Marian College (1996). He was also honored by receipt of the Anti-Defamation League's 2003 Man of Achievement Award, and the 2005 Hoosier Heritage Lifetime Achievement Award.

Robert J. Myerburg (Chairman)
Dr. Myerburg completed his undergraduate and medical training at Johns Hopkins University and the University of Maryland, respectively. He completed his internship at the University of Maryland Hospital and then joined the military to serve two years at the U.S. Public Health Service Heart Disease Control Program. He performed his residency in internal medicine at Charity Hospital at Tulane University, followed by a Fellowship in Cardiology at Emory University. After this he became a research fellow in the Department of Pharmacology at Columbia College of P&S in New York.

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2014 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us